Cargando…
Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis
BACKGROUND: Monitoring progress towards the WHO global target to eliminate hepatitis C virus (HCV) infection by 2030, entails reliable prevalence estimates for HCV infection in different populations. Little is known about the global burden of HCV infection in pregnant women. Here, for the first time...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692665/ https://www.ncbi.nlm.nih.gov/pubmed/38045801 http://dx.doi.org/10.1016/j.eclinm.2023.102327 |
_version_ | 1785152992822951936 |
---|---|
author | Abbasi, Farzaneh Almukhtar, Mustafa Fazlollahpour-Naghibi, Andarz Alizadeh, Faezeh Behzad Moghadam, Kimia Jafari Tadi, Mehrdad Ghadimi, Saleh Bagheri, Kimia Babaei, Hedye Bijani, Mohammad Hossein Rouholamin, Safoura Razavi, Maryam Rezaeinejad, Mahroo Chemaitelly, Hiam Sepidarkish, Mahdi Farid-Mojtahedi, Maryam Rostami, Ali |
author_facet | Abbasi, Farzaneh Almukhtar, Mustafa Fazlollahpour-Naghibi, Andarz Alizadeh, Faezeh Behzad Moghadam, Kimia Jafari Tadi, Mehrdad Ghadimi, Saleh Bagheri, Kimia Babaei, Hedye Bijani, Mohammad Hossein Rouholamin, Safoura Razavi, Maryam Rezaeinejad, Mahroo Chemaitelly, Hiam Sepidarkish, Mahdi Farid-Mojtahedi, Maryam Rostami, Ali |
author_sort | Abbasi, Farzaneh |
collection | PubMed |
description | BACKGROUND: Monitoring progress towards the WHO global target to eliminate hepatitis C virus (HCV) infection by 2030, entails reliable prevalence estimates for HCV infection in different populations. Little is known about the global burden of HCV infection in pregnant women. Here, for the first time to our knowledge, we estimated the global and regional seroprevalence of HCV antibody (Ab) and determinants in pregnant women. METHODS: In this systematic review and meta-analysis study, we searched PubMed/MEDLINE, Web of Science, Embase, Scopus, and SciELO databases for peer-reviewed observational studies between January 1, 2000 and April 1, 2023, without language or geographical restrictions. Pooled global seroprevalence (and 95% confidence interval, CI) were estimated using random-effects meta-analysis and seroprevalences were categorised according to World Health Organization regions and subregions, publishing year, countries’ income and human development index (HDI) levels. We used sensitivity analysis to assess the effect of four large sample size studies on pooled global prevalence through the “leave-one-out” method. We also investigated the association of potential risk factors with HCV seropositivity in pregnant women by subgroup and meta-regression analyses. The Protocol was registered in PROSPERO CRD42023423259. FINDINGS: We included 192 eligible studies (208 datasets), with data for 148,509,760 pregnant women from 53 countries. The global seroprevalence of HCV Ab in pregnant women was 1.80% (95% CI, 1.72–1.89%) and 3.29% (3.01–3.57%) in overall and sensitivity analyses, respectively. The seroprevalence was highest in the Eastern Mediterranean region (6.21%, 4.39–8.29%) and lowest in the Western Pacific region (0.75%, 0.38–1.22%). Subgroup analysis indicated that the seroprevalence of HCV Ab among pregnant women was significantly higher for those with opioid use disorder (51.94%, 95% CI: 37.32–66.39) and HIV infection (4.34%, 95% CI: 2.21–7.06%) than for the general population of pregnant women (1.08%, 95% CI: 1.02–1.15%), as confirmed by multivariable meta-regression (p < 0.001). A significant decreasing trend was observed with increasing human development index levels. Other important risk factors for HCV seropositivity included older age, lower educational levels, poly sexual activity, history of blood transfusion, hospitalization, surgery, abortion and sexual transmitted diseases, having scarification/tattoo or piercing, and testing hepatitis B positive. INTERPRETATION: This meta-analysis showed relatively high burden of exposure to HCV infection (2.2–5.3 million) in pregnant women globally. However, due to substantial heterogeneity between studies, our estimates might be different than the true seroprevalence. Our findings highlighted the need to expand HCV screening for women of reproductive age or during pregnancy, particularly in countries with high prevalence; as well as for more studies that assess safety of existing therapeutic drugs during pregnancy or potentially support development of drugs for pregnant women. FUNDING: There was no funding source for this study. |
format | Online Article Text |
id | pubmed-10692665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106926652023-12-03 Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis Abbasi, Farzaneh Almukhtar, Mustafa Fazlollahpour-Naghibi, Andarz Alizadeh, Faezeh Behzad Moghadam, Kimia Jafari Tadi, Mehrdad Ghadimi, Saleh Bagheri, Kimia Babaei, Hedye Bijani, Mohammad Hossein Rouholamin, Safoura Razavi, Maryam Rezaeinejad, Mahroo Chemaitelly, Hiam Sepidarkish, Mahdi Farid-Mojtahedi, Maryam Rostami, Ali eClinicalMedicine Articles BACKGROUND: Monitoring progress towards the WHO global target to eliminate hepatitis C virus (HCV) infection by 2030, entails reliable prevalence estimates for HCV infection in different populations. Little is known about the global burden of HCV infection in pregnant women. Here, for the first time to our knowledge, we estimated the global and regional seroprevalence of HCV antibody (Ab) and determinants in pregnant women. METHODS: In this systematic review and meta-analysis study, we searched PubMed/MEDLINE, Web of Science, Embase, Scopus, and SciELO databases for peer-reviewed observational studies between January 1, 2000 and April 1, 2023, without language or geographical restrictions. Pooled global seroprevalence (and 95% confidence interval, CI) were estimated using random-effects meta-analysis and seroprevalences were categorised according to World Health Organization regions and subregions, publishing year, countries’ income and human development index (HDI) levels. We used sensitivity analysis to assess the effect of four large sample size studies on pooled global prevalence through the “leave-one-out” method. We also investigated the association of potential risk factors with HCV seropositivity in pregnant women by subgroup and meta-regression analyses. The Protocol was registered in PROSPERO CRD42023423259. FINDINGS: We included 192 eligible studies (208 datasets), with data for 148,509,760 pregnant women from 53 countries. The global seroprevalence of HCV Ab in pregnant women was 1.80% (95% CI, 1.72–1.89%) and 3.29% (3.01–3.57%) in overall and sensitivity analyses, respectively. The seroprevalence was highest in the Eastern Mediterranean region (6.21%, 4.39–8.29%) and lowest in the Western Pacific region (0.75%, 0.38–1.22%). Subgroup analysis indicated that the seroprevalence of HCV Ab among pregnant women was significantly higher for those with opioid use disorder (51.94%, 95% CI: 37.32–66.39) and HIV infection (4.34%, 95% CI: 2.21–7.06%) than for the general population of pregnant women (1.08%, 95% CI: 1.02–1.15%), as confirmed by multivariable meta-regression (p < 0.001). A significant decreasing trend was observed with increasing human development index levels. Other important risk factors for HCV seropositivity included older age, lower educational levels, poly sexual activity, history of blood transfusion, hospitalization, surgery, abortion and sexual transmitted diseases, having scarification/tattoo or piercing, and testing hepatitis B positive. INTERPRETATION: This meta-analysis showed relatively high burden of exposure to HCV infection (2.2–5.3 million) in pregnant women globally. However, due to substantial heterogeneity between studies, our estimates might be different than the true seroprevalence. Our findings highlighted the need to expand HCV screening for women of reproductive age or during pregnancy, particularly in countries with high prevalence; as well as for more studies that assess safety of existing therapeutic drugs during pregnancy or potentially support development of drugs for pregnant women. FUNDING: There was no funding source for this study. Elsevier 2023-11-17 /pmc/articles/PMC10692665/ /pubmed/38045801 http://dx.doi.org/10.1016/j.eclinm.2023.102327 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Abbasi, Farzaneh Almukhtar, Mustafa Fazlollahpour-Naghibi, Andarz Alizadeh, Faezeh Behzad Moghadam, Kimia Jafari Tadi, Mehrdad Ghadimi, Saleh Bagheri, Kimia Babaei, Hedye Bijani, Mohammad Hossein Rouholamin, Safoura Razavi, Maryam Rezaeinejad, Mahroo Chemaitelly, Hiam Sepidarkish, Mahdi Farid-Mojtahedi, Maryam Rostami, Ali Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis |
title | Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis |
title_full | Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis |
title_fullStr | Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis |
title_full_unstemmed | Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis |
title_short | Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis |
title_sort | hepatitis c infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692665/ https://www.ncbi.nlm.nih.gov/pubmed/38045801 http://dx.doi.org/10.1016/j.eclinm.2023.102327 |
work_keys_str_mv | AT abbasifarzaneh hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT almukhtarmustafa hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT fazlollahpournaghibiandarz hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT alizadehfaezeh hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT behzadmoghadamkimia hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT jafaritadimehrdad hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT ghadimisaleh hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT bagherikimia hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT babaeihedye hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT bijanimohammadhossein hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT rouholaminsafoura hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT razavimaryam hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT rezaeinejadmahroo hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT chemaitellyhiam hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT sepidarkishmahdi hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT faridmojtahedimaryam hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis AT rostamiali hepatitiscinfectionseroprevalenceinpregnantwomenworldwideasystematicreviewandmetaanalysis |